Results 261 to 270 of about 6,543,071 (370)

Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting

Molecular Oncology, EarlyView.
CARtein is a modular CAR platform that uses split inteins to splice antigen‐recognition modules onto a universal signaling backbone, enabling precise, scarless assembly without re‐engineering signaling domains. Deployed here against CD19 and CD20 in B‐cell malignancies, the design supports flexible multi‐antigen targeting to boost T‐cell activation and
Pablo Gonzalez‐Garcia, Noelia Moares, Wenjie Yi‐He, Rosa Luna‐Espejo, Ricardo Fernandez‐Cisnal, Javier Ocaña‐Cuesta, Juan P. Muñoz‐Miranda, Antonio Gabucio, Cecilia M. Fernandez‐Ponce, Francisco Garcia‐Cozar   +9 more
wiley   +1 more source

Maximizing genetic gain over multiple generations with quantitative trait locus selection and control of inbreeding [PDF]

, 2004
Dekkers, J.C.M., Settar, P., Villanueva, B., Woolliams, John   +3 more
core  

Genetic Variance and Covariance Components for Feed Intake, Average Daily Gain, and Postweaning Gain in Growing Beef Cattle

, 2015
Kelli Retallick, Jennifer M Bormann, Robert L Weaber, M. D. MacNeil, H. L. Bradford, H. C. Freetly, W. M. Snelling, Mark Thallman, D. W. Moser, L. A. Kuehn   +9 more
openalex   +2 more sources

Research Article Genetic and phenotypical correlations, path analysis and genetic gain in two populations of corn with resistance to leaf spot, rust, and blight disease

, 2020
Adeliana Silva de Oliveira, Edésio Fialho dos Reis, Ana Paula Oliveira Nogueira, Daniel Bonifácio Oliveira Cardoso, Fernando Cézar Juliatti   +4 more
openalex   +1 more source

Genetic evaluation models for post-weaning weight gain in a multibreed Angus-Nelore population [PDF]

, 2019
Alan Miranda Prestes, Maurício Morgado de Oliveira, Fernanda Cristina Breda, Paulo Roberto Nogara Rorato, Jader Silva Lopes, Giovani Luis Feltes, André Padilha Bravo   +6 more
openalex   +1 more source

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

Molecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz, Anna L. Bartkowiak, Michael Rose, Nora Kolks, Patrick Petzsch, Vandana Solanki, Anne Stoffel, Bianca Faßbender, Leandra Lepping, Julka Volkamer, Karl Köhrer, Marc Seifert, Tokameh Mahmoudi, Tahlita C. M. Zuiverloon, Günter Niegisch, Michèle J. Hoffmann   +15 more
wiley   +1 more source

Genetic Gain and Inbreeding in Different Simulated Genomic Selection Schemes for Grain Yield and Oil Content in Safflower. [PDF]

Plants (Basel)
Zhao H, Khansefid M, Lin Z, Hayden MJ.
europepmc   +1 more source

Cytoplasmic p21 promotes stemness of colon cancer cells via activation of the NFκB pathway

Molecular Oncology, EarlyView.
Cytoplasmic p21 promotes colorectal cancer stem cell (CSC) features by destabilizing the NFκB–IκB complex, activating NFκB signaling, and upregulating BCL‐xL and COX2. In contrast to nuclear p21, cytoplasmic p21 enhances spheroid formation and stemness transcription factor CD133.
Arnatchai Maiuthed, Kerstin Huebner, Katharina Erlenbach‐Wuensch, Chuanpit Hampel, Daniela Thalheim, Adriana Vial‐Roehe, Bodee Nutho, Susanne Merkel, Arndt Hartmann, Pithi Chanvorachote, Regine Schneider‐Stock   +10 more
wiley   +1 more source

Multicentre analysis of patterns of DNA gains and losses in 204 neuroblastoma tumors: How many genetic subgroups are there? [PDF]

, 2001
Jo Vandesompele, Frank Speleman, Nadine Van Roy, Genevi�ve Laureys, C. Brinkschmidt, Holger Christiansen, Fritz Lampert, Maria Łastowska, Nick Bown, Andy D.J. Pearson, James C. Nicholson, Fiona Ross, Val�rie Combaret, Olivier Delattre, Burt G. Feuerstein, Dominique Plantaz   +15 more
openalex   +1 more source

Class IIa HDACs forced degradation allows resensitization of oxaliplatin‐resistant FBXW7‐mutated colorectal cancer

Molecular Oncology, EarlyView.
HDAC4 is degraded by the E3 ligase FBXW7. In colorectal cancer, FBXW7 mutations prevent HDAC4 degradation, leading to oxaliplatin resistance. Forced degradation of HDAC4 using a PROTAC compound restores drug sensitivity by resetting the super‐enhancer landscape, reprogramming the epigenetic state of FBXW7‐mutated cells to resemble oxaliplatin ...
Vanessa Tolotto, Nicolò Gualandi, Ylenia Cortolezzis, Raffaella Picco, Monica Colitti, Francesca D'Este, Mariachiara Gani, Wayne W. Hancock, Giovanni Terrosu, Cristina Degrassi, Francesca Agostini, Claudio Brancolini, Luigi E. Xodo, Eros Di Giorgio   +13 more
wiley   +1 more source